CLINICAL_TRIALS
trial_result
· 2021-07-07
Clinical Trial Update: Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC [Phase 2]
Summary
Phase 2 study evaluating the combination of almonertinib with concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Yuan Chen | Conditions: NSCLC, Stage III | Phase 2 | Status: UNKNOWN